RxDoctor Payments Data

Holly Johnson, MD

Ophthalmology · Raleigh, NCNPI 1043261076

Payments from drug & device makers

$5,673in general payments, 2019–2025

Across 125 payments — averaging $45.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Biotissue Holdings Inc.$959
  • AbbVie$894
  • Glaukos Corporation$543
  • Ocular Therapeutix, Inc.$271
  • Johnson & Johnson Surgical Vision, Inc.$258
  • plus $657 from 15 others

What the payments were for

  • Travel & lodging$65011%
  • Food & beverage$4,85586%
  • Gifts$1352%
  • Entertainment$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,673 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$179,697
Medicare patients
464
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost266$139,852
RestasisCyclosporine67$86,831
MieboPerfluorohexyloctane/Pf25$28,758
XiidraLifitegrast17$21,032
Alphagan PBrimonidine Tartrate37$10,702
VyzultaLatanoprostene Bunod13$6,748
Prednisolone Acetate64$3,457
SimbrinzaBrinzolamide/Brimonidine Tart15$3,200
CombiganBrimonidine Tartrate/Timolol13$3,144
Latanoprost154$2,336
Brimonidine Tartrate32$1,982
MoxifloxacinMoxifloxacin Hcl57$1,446
Dorzolamide Hcl69$1,366
Ketorolac Tromethamine50$1,207
Bimatoprost12$1,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$894$240,528383 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$19$56,53955 claims
AlconSimbrinza$2,090$3,20015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →